Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 27 December 2023

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Communication

Establishment of a Novel Anti-Mouse CCR1 Monoclonal Antibody C1Mab-6

Tsunenori Ouchida ⁺, Yu Isoda ⁺, Takuro Nakamura, Miyuki Yanaka, Tomohiro Tanaka, Saori Handa, Mika K. Kaneko, Hiroyuki Suzuki and Yukinari Kato ^{1,*}

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi 980-8575, Japan; mika.kaneko.d4@tohoku.ac.jp (M.K.K.); tomohiro.tanaka.b5@tohoku.ac.jp (T.T.)

* Correspondence: yukinari.kato.e6@tohoku.ac.jp (Y.K.); Tel.: +81-22-717-8207 (H.S. & Y.K.)

⁺ These authors contributed equally to this work.

Abstract: C-C motif chemokine receptor 1 (CCR1/CD191) is a member of G-protein-coupled receptors, and is expressed on myeloid cells, such as neutrophils and macrophages. Because the CCR1 signaling promotes tumor expansion in the tumor microenvironment (TME), the modification of TME is an effective strategy for cancer therapy. Although CCR1 is an attractive target for solid tumors and hematological malignancies, anti-CCR1 therapeutic agents have not been approved. Here, we established a novel anti-mouse CCR1 (mCCR1) monoclonal antibody (mAb), C1Mab-6 (rat IgG_{2b}, kappa), using the Cell-Based Immunization and Screening (CIBS) method. Flow cytometry and Western blot analyses showed that C1Mab-6 recognizes mCCR1 specifically. The dissociation constant of C1Mab-6 for mCCR1-overexpressed Chinese hamster ovary-K1 was determined as 3.9×10-9 M, indicating that C1Mab-6 possesses a high affinity to mCCR1. These results suggest that C1Mab-6 could be a useful tool for targeting CCR1 in preclinical mouse models.

Keywords: mouse CCR1; CBIS method; monoclonal antibody; flow cytometry

1. Introduction

(cc) (i)

C-C motif chemokine receptor 1 (CCR1), also known as CD191, is a member of G-proteincoupled receptors for many chemokines, such as CCL3, CCL5, CCL7, CCL8, CCL13, CCL14, CCL15, CCL16, and CCL23 in humans.[1] CCR1, which is expressed on neutrophils or macrophages, is important for the infiltration of these cells. The leukocyte infiltration process consists of three steps: i) tethering, rolling, and arrest on the vessel wall, ii) crawling on the endothelium, and iii) transendothelial migration.[2] CCR1 contributes to stable adhesion of crawling neutrophils on the endothelium in the joints in the K/BxN serum transferred mice (a murine model for rheumatoid arthritis [RA]).[3,4]

CCR1 signaling promotes tumor invasion and metastasis. The cis-Apc(+/Delta716) Smad4(+/-) mutant mice develop spontaneous invasive colorectal cancers.[5] However, CCR1-knockout in the background decreases the invasiveness of these tumors *in vivo*.[6] CCR1-positive myeloid cells accumulate at the tumor invasive front and drive tumor invasion by producing the matrix metalloproteinases such as MMP9 and MMP2.[7,8] Liver metastasis is observed in 25% of patients with colorectal cancers and is the main cause of death.[9,10] Analysis of disease-free survival (DFS) after curative liver resection showed that the DFS of patients with CCL15 (a CCR1 ligand)-positive liver metastases is shorter than that of CCL15-negative.[8] More CCR1-positive cells accumulated around the CCL15-positive metastases than CCR15-negative ones.[8] CCR1 signaling also plays a critical role in the development of a carcinogen-induced hepatocellular carcinoma model. The CCR1 deficiency in mice reduced the tumor development through suppression of neovascularization and intratumoral Kupffer cell accumulation.[11]

2

TME influences the tumor progression and responsiveness to therapies.[12] Modification of TME is a strategy for improving the effect of antitumor therapies.[13] Although CCR1 is an attractive target for modifying TME and suppressing tumor progression, few preclinical studies using antimouse CCR1 (mCCR1) monoclonal antibodies (mAbs) have been reported.[14]

Until now, we have developed mAbs for mouse CCR3[15], CCR8[16], and CXCR4[17] using the Cell-Based Immunization and Screening (CBIS) method.[18–25] In this study, we established a novel anti-mCCR1 mAb using the CBIS method and evaluated its applications.

2. Materials and Methods

2.1. Antibodies

The anti-mouse CCR1 mAb (clone S15040E)[26] was purchased from BioLegend (San Diego, CA). We previously developed RcMab-1 against isocitrate dehydrogenase 1.[27] An anti-DYKDDDDK mAb (clone 1E6) was purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). Alexa Fluor 488-conjugated anti-rat IgG was purchased from Cell Signaling Technology, Inc. (Danvers, MA). HRP-conjugated anti-rat IgG (A9542) and HRP-conjugated anti-mouse IgG (P0260) were purchased from Sigma-Aldrich (St. Louis, MO) and Agilent Technologies, Inc. (Santa Clara, CA), respectively.

2.2. Animals

A five-week-old Sprague–Dawley rat was purchased from CLEA Japan (Tokyo, Japan). The animal was housed under specific pathogen-free conditions. All animal experiments were approved by the Animal Care and Use Committee of Tohoku University (Permit number: 2022MdA-001).

2.3. Cell lines

LN229, Chinese hamster ovary (CHO)-K1, and P3X63Ag8U.1 (P3U1) cells were obtained from the American Type Culture Collection (Manassas, VA). pCMV6neo-myc-DDK vector with mCCR1 (Accession No.: NM_009912) was purchased from OriGene Technologies, Inc. (Rockville, MD). The plasmid was transfected into the cell lines using a Neon transfection system (Thermo Fisher Scientific, Inc., Waltham, MA). Subsequently, LN229 and CHO-K1, which stably overexpressed mCCR1 with C-terminal myc-DDK tags (hereinafter described as LN229/mCCR1 and CHO/mCCR1, respectively) were established using a cell sorter (SH800; Sony Corp., Tokyo, Japan), following cultivation in a medium containing 0.5 mg/mL G418 (Nacalai Tesque, Inc., Kyoto, Japan).

CHO-K1, P3U1, and CHO/mCCR1 were also cultured in a Roswell Park Memorial Institute (RPMI) 1640 medium (Nacalai Tesque, Inc.) that was supplemented with 10% heat-inactivated fetal bovine serum (FBS, Thermo Fisher Scientific Inc.), 100 units/mL penicillin, 100 μ g/mL streptomycin, and 0.25 μ g/mL amphotericin B (Nacalai Tesque, Inc.). LN229 and LN229/mCCR1 were cultured in a Dulbecco's Modified Eagle Medium (DMEM; Nacalai Tesque, Inc.) that was supplemented as shown above. Then, cells were grown in a humidified incubator, which was supplied with 5% CO₂ and 95% air at 37°C.

2.4. Hybridoma production

For developing anti-mCCR1 mAbs, a six-week-old female Sprague-Dawley rat (CLEA Japan, Tokyo, Japan) was immunized intraperitoneally with 1 × 10⁹ cells of CHO/mCCR1. The immunogen was harvested after brief exposure to 1 mM ethylenediaminetetraacetic acid (EDTA; Nacalai Tesque, Inc.). We added Alhydrogel adjuvant 2% (InvivoGen, San Diego, CA) as an adjuvant in the first immunization. Three additional injections of 1 × 10⁹ cells of CHO/mCCR1 were performed without an adjuvant every week. We performed a final booster immunization of 1 × 10⁹ cells of CHO/mCCR1 intraperitoneally two days before harvesting splenocytes. We fused the harvested splenocytes with P3U1 cells using polyethylene glycol 1500 (PEG1500; Roche Diagnostics, Indianapolis, IN). Hybridoma cells were cultured in the RPMI1640 medium, supplemented as shown above. We further

3

added hypoxanthine, aminopterin, and thymidine (HAT; Thermo Fisher Scientific, Inc.), 5% Briclone (NICB, Dublin, Ireland), and 5 μ g/mL of plasmocin into the medium. The hybridoma supernatants were screened by flow cytometry using LN229/mCCR1 and parental LN229. The culture supernatants of hybridomas were filtrated and purified using Ab-Capcher Extra (ProteNova, Kagawa, Japan).

2.5. Flow cytometry

CHO-K1, CHO/mCCR1, LN229, and LN229/mCCR1 cells were harvested by exposure to 1 mM ethylenediaminetetraacetic acid (EDTA, Nacalai Tesque). The cells were washed with 0.1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) and treated with anti-mCCR1 mAbs for 30 min at 4°C. After washing, the cells were treated with Alexa Fluor 488-conjugated anti-rat IgG. Flow cytometric analysis was performed using the SA3800 Cell Analyzer (Sony, Tokyo, Japan).

2.6. Determination of the binding affinity by flow cytometry

The dissociation constants (*K*_D) were suspended in 100 μ L serially diluted anti-mCCR1 mAbs (100 μ g/mL to 6 ng/mL), after which Alexa Fluor 488-conjugated anti-rat IgG (1:200) were added. Fluorescence data were subsequently collected, using an SA3800 Cell Analyzer (Sony Corp.), following the calculation of the dissociation constant (*K*_D) by fitting the binding isotherms into the built-in; one-site binding model in GraphPad PRISM 10 (GraphPad Software, Inc., La Jolla, CA).

2.7. Western blot analysis

Cell lysates (10 µg) were boiled in sodium dodecyl sulfate (SDS) sample buffer (Nacalai Tesque, Inc.), after which proteins were separated on 5%–20% polyacrylamide gels (FUJIFILM Wako Pure Chemical Corporation) and transferred to polyvinylidene difluoride membranes (Merck KGaA). After blocking with 4% skim milk (Nacalai Tesque, Inc.) in 0.05% Tween 20-containing PBS, membranes were incubated with 0.1 µg/mL of anti-DYKDDDDK or 1 µg/mL of the other primary mAbs. Then, they were incubated again with horseradish peroxidase (HRP)-conjugated anti-rat immunoglobulins (for anti-CCR1 mAbs and RcMab-1; diluted 1:10,000) or anti-mouse immunoglobulins (for anti-DYKDDDDK; diluted 1:1,000). Finally, protein bands were detected using ImmunoStar LD (FUJIFILM Wako Pure Chemical Corporation) with a Sayaca-Imager (DRC Co. Ltd., Tokyo, Japan).

3. Results

3.1. Establishment of anti-mCCR1 antibodies

We used the CBIS method to establish novel an anti-mCCR1 antibody (Figure 1). The CBIS method is a high-throughput method for the establishment of antibodies against membrane proteins. CBIS method consists of two main steps: immunization of antigen-overexpressing cells (Figure 1A) and screening of hybridoma supernatants using flow cytometry (Figure 1B). After immunization of CHO/mCCR1 and screening of hybridoma supernatants with LN229/mCCR1, C1Mab-6 (rat IgG_{2b}, kappa) was finally developed.

A. Immunization of CHO/mCCR1





Cloning (limiting dilution)

Figure 1. The scheme of establishment of C1Mab-6 by CBIS method. (A) CHO/mCCR1-mycDDK cells were injected intraperitoneally into a Sprague–Dawley rat. The splenocytes of the rat were fused with P3U1 cells and seeded in 96 well plates. (B) The culture supernatants of each well were screened through flow cytometry to distinguish anti-mCCR1 mAb-producing hybridomas. C1Mab-6 was established by limiting dilution and some additional screenings.

3.2. Flow cytometry using anti-CCR1 mAbs

To check the specificity and reactivity of C₁Mab-6, we performed flow cytometry against LN229/mCCR1, LN229, CHO/mCCR1, and CHO-K1. S15040E is a commercially available mAb[26] and was used as a positive control in this study. C₁Mab-6 bound to LN229/mCCR1 and CHO/mCCR1 cells in a dose-dependent manner (Figures 2A and 3A). In contrast, S15040E exhibited lower reactivity against both cells compared to C₁Mab-6. C₁Mab-6 and S15040E did not react with LN229 cells and CHO-K1 even at 10 μ g/mL (Figures 2B and 3B), indicating that both mAbs are specific to mCCR1.





Figure 2. Flow cytometry of anti-CCR1 mAbs against LN229/mCCR1. LN229/mCCR1 (A) and LN229 (B) cells were treated with 0.1–10 μ g/mL of C₁Mab-6 or S15040E, followed by treatment with Alexa Fluor 488-conjugated anti-rat IgG antibodies. The red lines show the cells treated with each mAb. The black lines show the cells treated with blocking buffer and Alexa Fluor 488-conjugated anti-rat IgG antibodies (negative control).





Figure 3. Flow cytometry of anti-CCR1 mAbs against CHO/mCCR1. CHO/mCCR1 (A) and CHO-K1 (B) cells were treated with $0.1-10 \mu$ g/mL of C1Mab-6 or S15040E, followed by treatment with Alexa Fluor 488-conjugated anti-rat IgG antibodies. The red lines show the cells treated with each mAb. The black lines show the cells treated with blocking buffer and Alexa Fluor 488-conjugated anti-rat IgG antibodies (negative control).

3.3. Determination of dissociation constant of anti-CCR1 mAbs

Next, we determined the dissociation constant (*K*_D) of anti-CCR1 mAbs against mCCR1, which is expressed on the cell surface using flow cytometry. The geometric mean of the fluorescence intensity at each concentration of C₁Mab-6 and S15040E was plotted. By fitting one-site binding models, the *K*_D values of C₁Mab-6 and S15040E for LN299/mCCR1 were determined as 1.0×10^{-8} M and 1.7×10^{-7} M, respectively (Figure 4A and 4B). Furthermore, the *K*_D values of C₁Mab-6 and S15040E for CHO/mCCR1 were calculated as 3.9×10^{-9} M and 3.5×10^{-8} M, respectively (Figure 4C and 4D), indicating that C₁Mab-6 possesses much higher affinity than S15040E.





Figure 4. Kinetic analyses of anti-CCR1 mAbs against mCCR1-overexpressed cells. The binding affinity of C1Mab-6 and S15040E against LN229/mCCR1 cells (A and B) and CHO/mCCR1 cells (C and D) were determined by flow cytometry. The dots show the geometric mean of fluorescence intensity at each concentration. The solid lines are the fitting curve calculated by GraphPad PRISM 6.

3.4. Western blot using anti-CCR1 mAbs

Finally, we performed Western blot analysis using anti-CCR1 mAbs. Lysates of CHO-K1 and CHO/mCCR1 were probed. The molecular weight of mCCR1-mycDDK is about 44,000. C1Mab-6 and an anti-DYKDDDDK mAb (clone 1E6) detected mCCR1 as about a 44-kDa band from lysates of CHO/mCCR1 (Figure 5) although S15040E could not detect mCCR1 in the lysates of CHO/mCCR1. C1Mab-6 did not detect any bands from the lysates of CHO-K1, indicating that C1Mab-6 can recognize mCCR1 specifically in Western blot analysis.



Figure 5. Kinetic analyses of anti-CCR1 mAbs against mCCR1-overexpressed cells. The binding affinity of C1Mab-6 and S15040E against LN229/mCCR1 cells (A and B) and CHO/mCCR1 cells (C and D) were determined by flow cytometry. The dots show the geometric mean of fluorescence intensity at each concentration. The solid lines are the fitting curve calculated by GraphPad PRISM 6.

4. Discussion

Anti-CCR1 therapies are potential treatments to improve the quality of life of multiple myeloma (MM) patients. MM is an incurable plasma B-cell malignancy.[28] Systemic osteopenia is observed in most MM patients.[29] Osteopenia causes bone fractures and impacts their quality of life. Serum levels of CCL3 are elevated in MM patients and correlate with the extent of bone disease.[30] MM cells produce CCL3, which activates osteoclast.[31,32] Neutralization of CCL3 with anti-CCL3 antibodies blocks osteolysis in mice.[32] CCL3 is a ligand activating CCR1 and CCR5.[1] CCX721, a small molecule antagonist against CCR1 not CCR5, dramatically reduced the osteolysis induced by 5TGM1, a murine MM cell line.[33] Additionally, CCX721 also reduces tumor burden of 5TGM1 cells inoculated intravenously.[33] These results indicated that CCR1 blockage inhibits tumor burden and osteolysis by MM through modifying the bone marrow microenvironment.

RA is a chronic inflammatory disease characterized by massive infiltration of synovial tissue and synovial fluid with immune cells in affected joints.[34] CCR1 is abundantly expressed by RA monocytes/macrophages, which mediate the inflammation at these sites.[35] CCX354, an analog of CCX721, was developed for the treatment of RA.[36] CCX354 exhibited good safety and clinical activities to RA patients in a Phase II study.[37] However, once daily oral administration is needed because the half-life of CCX354 in the plasma of humans is approximately 6 h.[36] Antibodies are therapeutic drugs stable in serum (the half-life of antibodies is around 3 weeks).[38] C1Mab-6 can bind to mCCR1-expressed cells with a high affinity (Figure 4). C1Mab-6 could be useful tools for developing anti-CCR1 therapies in preclinical murine models.

References

- 1. Stone, M.J.; Hayward, J.A.; Huang, C.; Z, E.H.; Sanchez, J. Mechanisms of Regulation of the Chemokine-Receptor Network. *Int J Mol Sci* 2017, *18*, doi:10.3390/ijms18020342.
- 2. Ley, K.; Laudanna, C.; Cybulsky, M.I.; Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol* **2007**, *7*, 678-689, doi:10.1038/nri2156.
- Miyabe, Y.; Miyabe, C.; Murooka, T.T.; Kim, E.Y.; Newton, G.A.; Kim, N.D.; Haribabu, B.; Luscinskas, F.W.; Mempel, T.R.; Luster, A.D. Complement C5a Receptor is the Key Initiator of Neutrophil Adhesion Igniting Immune Complex-induced Arthritis. *Sci Immunol* 2017, 2, doi:10.1126/sciimmunol.aaj2195.
- 4. Christensen, A.D.; Haase, C.; Cook, A.D.; Hamilton, J.A. K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis. *Front Immunol* **2016**, *7*, 213, doi:10.3389/fimmu.2016.00213.
- Takaku, K.; Oshima, M.; Miyoshi, H.; Matsui, M.; Seldin, M.F.; Taketo, M.M. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. *Cell* 1998, 92, 645-656, doi:10.1016/s0092-8674(00)81132-0.
- Kitamura, T.; Kometani, K.; Hashida, H.; Matsunaga, A.; Miyoshi, H.; Hosogi, H.; Aoki, M.; Oshima, M.; Hattori, M.; Takabayashi, A.; et al. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. *Nat Genet* 2007, *39*, 467-475, doi:10.1038/ng1997.
- Hirai, H.; Fujishita, T.; Kurimoto, K.; Miyachi, H.; Kitano, S.; Inamoto, S.; Itatani, Y.; Saitou, M.; Maekawa, T.; Taketo, M.M. CCR1-mediated accumulation of myeloid cells in the liver microenvironment promoting mouse colon cancer metastasis. *Clin Exp Metastasis* 2014, *31*, 977-989, doi:10.1007/s10585-014-9684-z.
- Itatani, Y.; Kawada, K.; Fujishita, T.; Kakizaki, F.; Hirai, H.; Matsumoto, T.; Iwamoto, M.; Inamoto, S.; Hatano, E.; Hasegawa, S.; et al. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. *Gastroenterology* 2013, 145, 1064-1075 e1011, doi:10.1053/j.gastro.2013.07.033.
- 9. Engstrand, J.; Nilsson, H.; Stromberg, C.; Jonas, E.; Freedman, J. Colorectal cancer liver metastases a population-based study on incidence, management and survival. *BMC Cancer* **2018**, *18*, 78, doi:10.1186/s12885-017-3925-x.
- Zhou, H.; Liu, Z.; Wang, Y.; Wen, X.; Amador, E.H.; Yuan, L.; Ran, X.; Xiong, L.; Ran, Y.; Chen, W.; et al. Colorectal liver metastasis: molecular mechanism and interventional therapy. *Signal Transduct Target Ther* 2022, 7, 70, doi:10.1038/s41392-022-00922-2.
- Yang, X.; Lu, P.; Fujii, C.; Nakamoto, Y.; Gao, J.L.; Kaneko, S.; Murphy, P.M.; Mukaida, N. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. *Int J Cancer* 2006, *118*, 1869-1876, doi:10.1002/ijc.21596.
- 12. de Visser, K.E.; Joyce, J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. *Cancer Cell* **2023**, *41*, 374-403, doi:10.1016/j.ccell.2023.02.016.

9

- Cheng, Y.Q.; Wang, S.B.; Liu, J.H.; Jin, L.; Liu, Y.; Li, C.Y.; Su, Y.R.; Liu, Y.R.; Sang, X.; Wan, Q.; et al. Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours. *Cell Prolif* 2020, *53*, e12865, doi:10.1111/cpr.12865.
- Kiyasu, Y.; Kawada, K.; Hirai, H.; Ogawa, R.; Hanada, K.; Masui, H.; Nishikawa, G.; Yamamoto, T.; Mizuno, R.; Itatani, Y.; et al. Disruption of CCR1-mediated myeloid cell accumulation suppresses colorectal cancer progression in mice. *Cancer Lett* 2020, 487, 53-62, doi:10.1016/j.canlet.2020.05.028.
- Asano, T.; Suzuki, H.; Tanaka, T.; Saito, M.; Li, G.; Goto, N.; Nanamiya, R.; Kaneko, M.K.; Kato, Y. C(3)Mab-3: A Monoclonal Antibody for Mouse CC Chemokine Receptor 3 for Flow Cytometry. *Monoclon Antib Immunodiagn Immunother* 2022, 41, 74-79, doi:10.1089/mab.2021.0062.
- Tanaka, T.; Nanamiya, R.; Takei, J.; Nakamura, T.; Yanaka, M.; Hosono, H.; Sano, M.; Asano, T.; Kaneko, M.K.; Kato, Y. Development of Anti-Mouse CC Chemokine Receptor 8 Monoclonal Antibodies for Flow Cytometry. *Monoclon Antib Immunodiagn Immunother* 2021, 40, 65-70, doi:10.1089/mab.2021.0005.
- 17. Ouchida, T.; Suzuki, H.; Tanaka, T.; Kaneko, M.K.; Kato, Y. Cx(4)Mab-1: A Novel Anti-Mouse CXCR4 Monoclonal Antibody for Flow Cytometry. *Monoclon Antib Immunodiagn Immunother* **2023**, doi:10.1089/mab.2023.0023.
- Hosono, H.; Asano, T.; Takei, J.; Sano, M.; Tanaka, T.; Kaneko, M.K.; Kato, Y. Development of an Anti-Elephant Podoplanin Monoclonal Antibody PMab-265 for Flow Cytometry. *Monoclon Antib Immunodiagn Immunother* 2021, 40, 141-145, doi:10.1089/mab.2021.0015.
- Takei, J.; Asano, T.; Nanamiya, R.; Nakamura, T.; Yanaka, M.; Hosono, H.; Tanaka, T.; Sano, M.; Kaneko, M.K.; Harada, H.; et al. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry. *Monoclon Antib Immunodiagn Immunother* 2021, 40, 71-75, doi:10.1089/mab.2021.0006.
- Tanaka, T.; Asano, T.; Sano, M.; Takei, J.; Hosono, H.; Nanamiya, R.; Nakamura, T.; Yanaka, M.; Harada, H.; Fukui, M.; et al. Development of Monoclonal Antibody PMab-269 Against California Sea Lion Podoplanin. *Monoclon Antib Immunodiagn Immunother* 2021, 40, 124-133, doi:10.1089/mab.2021.0011.
- 21. Goto, N.; Suzuki, H.; Tanaka, T.; Asano, T.; Kaneko, M.K.; Kato, Y. Development of a Monoclonal Antibody PMab-292 Against Ferret Podoplanin. *Monoclon Antib Immunodiagn Immunother* **2022**, *41*, 101-109, doi:10.1089/mab.2021.0067.
- 22. Li, G.; Suzuki, H.; Asano, T.; Tanaka, T.; Suzuki, H.; Kaneko, M.K.; Kato, Y. Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications. *Antibodies (Basel)* **2022**, *11*, doi:10.3390/antib11020041.
- Nanamiya, R.; Suzuki, H.; Takei, J.; Li, G.; Goto, N.; Harada, H.; Saito, M.; Tanaka, T.; Asano, T.; Kaneko, M.K.; et al. Development of Monoclonal Antibody 281-mG(2a)-f Against Golden Hamster Podoplanin. *Monoclon Antib Immunodiagn Immunother* 2022, 41, 311-319, doi:10.1089/mab.2021.0058.
- 24. Goto, N.; Suzuki, H.; Tanaka, T.; Ishikawa, K.; Ouchida, T.; Kaneko, M.K.; Kato, Y. EMab-300 Detects Mouse Epidermal Growth Factor Receptor-Expressing Cancer Cell Lines in Flow Cytometry. *Antibodies (Basel)* **2023**, *12*, doi:10.3390/antib12030042.
- 25. Suzuki, H.; Tanaka, T.; Kudo, Y.; Tawara, M.; Hirayama, A.; Kaneko, M.K.; Kato, Y. A Rat Anti-Mouse CD39 Monoclonal Antibody for Flow Cytometry. *Monoclon Antib Immunodiagn Immunother* **2023**, doi:10.1089/mab.2023.0018.
- 26. Du, X.; Li, F.; Zhang, C.; Li, N.; Huang, H.; Shao, Z.; Zhang, M.; Zhan, X.; He, Y.; Ju, Z.; et al. Eosinophilderived chemokine (hCCL15/23, mCCL6) interacts with CCR1 to promote eosinophilic airway inflammation. *Signal Transduct Target Ther* **2021**, *6*, 91, doi:10.1038/s41392-021-00482-x.
- 27. Kato Kaneko, M.; Ogasawara, S.; Kato, Y. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. *Tohoku J Exp Med* **2013**, *230*, 103-109, doi:10.1620/tjem.230.103.
- Puertas, B.; Gonzalez-Calle, V.; Sobejano-Fuertes, E.; Escalante, F.; Queizan, J.A.; Barez, A.; Labrador, J.; Alonso-Alonso, J.M.; Garcia de Coca, A.; Cantalapiedra, A.; et al. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. *Cancers (Basel)* 2023, 15, doi:10.3390/cancers15051558.
- 29. Hiasa, M.; Harada, T.; Tanaka, E.; Abe, M. Pathogenesis and treatment of multiple myeloma bone disease. *Jpn Dent Sci Rev* **2021**, *57*, 164-173, doi:10.1016/j.jdsr.2021.08.006.
- 30. Terpos, E.; Politou, M.; Szydlo, R.; Goldman, J.M.; Apperley, J.F.; Rahemtulla, A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. *Br J Haematol* **2003**, *123*, 106-109, doi:10.1046/j.1365-2141.2003.04561.x.
- 31. Vallet, S.; Pozzi, S.; Patel, K.; Vaghela, N.; Fulciniti, M.T.; Veiby, P.; Hideshima, T.; Santo, L.; Cirstea, D.; Scadden, D.T.; et al. A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. *Leukemia* **2011**, *25*, 1174-1181, doi:10.1038/leu.2011.43.
- 32. Oyajobi, B.O.; Franchin, G.; Williams, P.J.; Pulkrabek, D.; Gupta, A.; Munoz, S.; Grubbs, B.; Zhao, M.; Chen, D.; Sherry, B.; et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor

burden in the murine 5TGM1 model of myeloma bone disease. *Blood* **2003**, *102*, 311-319, doi:10.1182/blood-2002-12-3905.

- Dairaghi, D.J.; Oyajobi, B.O.; Gupta, A.; McCluskey, B.; Miao, S.; Powers, J.P.; Seitz, L.C.; Wang, Y.; Zeng, Y.; Zhang, P.; et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. *Blood* 2012, 120, 1449-1457, doi:10.1182/blood-2011-10-384784.
- 34. Haringman, J.J.; Ludikhuize, J.; Tak, P.P. Chemokines in joint disease: the key to inflammation? *Ann Rheum Dis* **2004**, *63*, 1186-1194, doi:10.1136/ard.2004.020529.
- 35. Katschke, K.J., Jr.; Rottman, J.B.; Ruth, J.H.; Qin, S.; Wu, L.; LaRosa, G.; Ponath, P.; Park, C.C.; Pope, R.M.; Koch, A.E. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. *Arthritis Rheum* **2001**, *44*, 1022-1032, doi:10.1002/1529-0131(200105)44:5<1022::Aid-anr181>3.0.Co;2-n.
- 36. Dairaghi, D.J.; Zhang, P.; Wang, Y.; Seitz, L.C.; Johnson, D.A.; Miao, S.; Ertl, L.S.; Zeng, Y.; Powers, J.P.; Pennell, A.M.; et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. *Clin Pharmacol Ther* 2011, *89*, 726-734, doi:10.1038/clpt.2011.33.
- 37. Tak, P.P.; Balanescu, A.; Tseluyko, V.; Bojin, S.; Drescher, E.; Dairaghi, D.; Miao, S.; Marchesin, V.; Jaen, J.; Schall, T.J.; et al. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. *Ann Rheum Dis* 2013, 72, 337-344, doi:10.1136/annrheumdis-2011-201605.
- 38. Morell, A.; Terry, W.D.; Waldmann, T.A. Metabolic properties of IgG subclasses in man. *J Clin Invest* **1970**, 49, 673-680, doi:10.1172/JCI106279.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.